A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP [abstract] - Nakagawa, K; Kiura, K; Nishio, M (J Clin Oncol)
2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition); 31(15): 8033